Luye Pharma’s Boan Biotechnology Partners with GenScript on GenCircle dsDNA Development
Shandong Boan Biotechnology Co., Ltd, a controlling subsidiary of China-based Luye Pharma Group (HKG: 2186),...
Cell-therapy
Suzhou Porton Biologics and Synbio Technologies Partner to Advance Cell and Gene Therapy in China
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...
China’s NHC Releases Draft Guidelines for Somatic Cell Clinical Research, Seeks Public Input
The National Health Commission (NHC) has released the “Somatic Cell Clinical Research Guidelines (draft proposal)”...
Shunxi Holding Group Secures Licensing Deal for Cartherics’ CTH-004 in Greater China
China-based Shunxi Holding Group Co. Ltd has entered into a licensing deal with Australia-based firm...
Meihua International Medical Expands with New Healthcare Industrial Park in Hainan
Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA), has announced the acquisition of a land...
Cellular Biomedicine Group Inc. and Janssen Biotech, Inc. Announce Global Collaboration for CAR-T Therapies
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG), emerging from a merger deal in...
GenScript Biotech’s Subsidiary Legend Biotech Announces Positive CAR-T Therapy Results
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...
Legend Biotech’s Carvykti Data Boosts Stock Price by 19.64% on Positive Phase III Results
Shares of Legend Biotech (NASDAQ: LEGN) jumped an impressive 19.64% in a single day, attributed...
CARSgen Therapeutics’ CT041 Receives NMPA Approval for Post-Operative Pancreatic Cancer Therapy
China-based chimeric antigen receptor (CAR)-T cell specialist, CARSgen Therapeutics Holdings Ltd (HKG: 2171), has announced...
Biosyngen Receives US FDA IND Approval for T-Cell Redirection Therapy for EBV-Positive Lymphoma
Biosyngen Pte Ltd, a cell and gene therapy (CGT) biotech with operations in Singapore and...
Ubrigene Secures RMB 150 Million in Series C+ Financing to Expand Global CGT CDMO Platform
Yiming Cell Biotechnology Co., Ltd, known as Ubrigene Biosciences Inc., a leading gene and cell...
CBMG’s C-CAR031 Shows Promising Results in Phase I Study for Hepatocellular Carcinoma
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has published the results of the...
PackGene Secures Series C Financing to Boost AAV Innovation and Global Expansion
China-based PackGene Biotech has announced the successful completion of a Series C financing round, securing...
Zephyrm Bioscience Secures Over RMB 200 Million in Series B Financing for Stem-Cell Drug Development
Zephyrm Bioscience, a prominent stem cell drug developer headquartered in Suzhou, has reportedly secured more...
VintaBio Secures $64M Funding to Revolutionize Viral Vectors for Cell and Gene Therapy
New biotech VintaBio, founded in Philadelphia, Pennsylvania (United States), announces the appointment of CEO David...
JW Therapeutics’ Carteyva Receives NMPA Approval for Moderate-to-Severe SLE Clinical Trial
China-based JW Therapeutics (HKG: 2126) has announced receiving tacit clinical trial approval from the National...
Jiangsu Hillgene Biopharma Secures Tens of Millions in Series A Financing for Cell Therapy R&D
China-based cell therapy-focused Contract Development and Manufacturing Organization (CDMO) Jiangsu Hillgene Biopharma Co., Ltd has...
Forecyte Bio Expands with New Cell and Gene Therapy GMP Facility in Shanghai
Maryland-based Contract Development and Manufacturing Organization (CDMO) Forecyte Biotechnologies has announced the opening of a...
Vcanbio Receives CDE Approval for VUM02 Clinical Trial in Idiopathic Pulmonary Fibrosis
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...
WuXi Advanced Therapies (WuXi ATU) Closes Manufacturing Facilities in Shanghai Due to Market Changes
Media reports indicate that WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused Contract...